Duck Hepatitis A Virus Genotypes

Overview and Taxonomy of Duck Hepatitis A Virus Genotypes

Taxonomic Classification and Virological Context

Duck hepatitis A virus (DHAV) occupies a singular and economically critical position within the picornavirus landscape, representing the sole recognized species, Avihepatovirus ahepati, within the genus Avihepatovirus, family Picornaviridae [10, 12]. This taxonomic distinction underscores the virus's unique evolutionary trajectory among avian picornaviruses, as it is the only member of this genus known to cause acute, highly fatal hepatitis in ducklings. The World Organisation for Animal Health (WOAH) classifies duck viral hepatitis (DVH) as a notifiable disease due to its rapid transmission and devastating impact on duck production systems globally, causing mortality rates that can approach 100% in susceptible ducklings under one week of age [12, 15]. The Food and Agriculture Organization (FAO) has also highlighted DHAV as a significant constraint to duck farming intensification in Asia and Africa, where duck meat and egg production represent critical protein sources and economic livelihoods.

The DHAV virion is a non-enveloped, icosahedral particle approximately 30 nm in diameter, harboring a single-stranded, positive-sense RNA genome that ranges from 7,690 to 7,769 nucleotides in length, excluding the poly(A) tail [2, 14, 23]. The genome organization follows the typical picornavirus architecture: a single open reading frame (ORF) encoding a large polyprotein of approximately 2,249 amino acids, flanked by a 5′ untranslated region (UTR) of approximately 653 nucleotides and a 3′ UTR of approximately 366 nucleotides [2]. The polyprotein is co- and post-translationally cleaved by viral proteases into structural proteins (VP0, VP3, and VP1) that form the capsid, and non-structural proteins (2A1, 2A2, 2B, 2C, 3A, 3B, 3C, and 3D) essential for replication and proteolytic processing [2, 21].

Historical Emergence and Genotype Classification

The first documented outbreaks of DVH occurred in the United States in 1945, and the causative agent, now designated DHAV genotype 1 (DHAV-1), was subsequently identified and characterized [15]. For decades, DHAV-1 was considered the sole etiological agent of DVH worldwide, and vaccination programs were developed exclusively against this genotype. However, the discovery of DHAV genotype 2 (DHAV-2) in Taiwan in the 1970s, followed by the identification of DHAV genotype 3 (DHAV-3) in South Korea and China in the early 2000s, fundamentally altered our understanding of the virus's genetic diversity and evolutionary capacity [9, 12, 18]. These three genotypes, DHAV-1, DHAV-2, and DHAV-3, constitute the officially recognized taxonomic framework for this virus, though recent evidence suggests that the intratypic diversity within each genotype may be far greater than previously appreciated.

The genetic demarcation between genotypes is defined by significant nucleotide and amino acid divergence across the genome. Phylogenetic analyses of the VP1 gene, which encodes the major capsid protein responsible for receptor binding and neutralization, reveal inter-genotypic nucleotide identities of approximately 67–74% and amino acid identities of approximately 74–89% [1, 8]. In contrast, intra-typic nucleotide identities typically exceed 90% [1, 2, 8]. The VP1 gene has become the primary molecular target for genotyping due to its high variability and direct relevance to antigenicity and vaccine efficacy [3, 4, 22].

DHAV Genotype 1: The Classic Lineage

DHAV-1, historically referred to as DHV-1 or DHAV serotype 1, remains the most widely distributed and extensively studied genotype [15, 17]. It was the sole genotype responsible for global DVH outbreaks from the 1940s until the late 1990s and continues to circulate endemically in duck-producing regions across Asia, Africa, and parts of Europe [1, 11, 15, 16]. The genome of DHAV-1 is approximately 7,692 nucleotides in length, and complete genome sequencing has revealed a high degree of conservation in the non-structural proteins, particularly the 3D RNA-dependent RNA polymerase and 3C protease domains [2, 21, 23].

Phylogenetic analyses of DHAV-1 strains have consistently resolved multiple genetic groups or sub-genotypes. Early classification schemes, based on codon usage bias and phylogenetic analysis of open reading frames, identified three major genotypes (A, B, and C) among DHV strains, with all classical DHAV-1 strains clustering within genotype C [9]. More recent and comprehensive analyses, utilizing complete genome sequences and VP1 gene datasets from Egypt, China, and Vietnam, have refined this classification. Egyptian DHAV-1 isolates, for instance, have been shown to cluster into at least four distinct genetic groups (Groups 1–4), with recent field isolates predominantly falling into Group 4, while older vaccine and reference strains occupy Groups 1–3 [16, 17, 19]. The Egyptian vaccine strain, widely used for immunization programs, clusters within Group 1 and exhibits only 67.6–74.4% nucleotide identity with contemporary DHAV-3 field isolates, highlighting the substantial genetic distance between genotypes [1, 7].

The VP1 protein of DHAV-1 contains multiple hypervariable regions (HVRs) that are critical determinants of antigenic variability. Studies have identified three distinct HVRs in the carboxyl-terminal region of VP1, with amino acid substitutions at positions such as I180T, G184E, D193N, and M213I differentiating field isolates from vaccine strains [17]. Importantly, a highly conserved B-cell epitope, 173LPAPTS178, has been identified on the VP1 protein of DHAV-1, which is recognized by neutralizing monoclonal antibodies [6]. This epitope is remarkably conserved across DHAV-1 isolates globally, suggesting functional constraints that limit its variability. However, a recent escape mutation at position S178Y was identified in an Egyptian field isolate (Du/Egy/Benha/2020/DHAV-1), which raises concerns about potential immune evasion and the long-term efficacy of current vaccines [11].

DHAV Genotype 3: The Emerging Dominant Subtype

DHAV-3 has supplanted DHAV-1 as the most prevalent and economically significant genotype in East Asia and has been increasingly detected in South and Southeast Asia, the Middle East, and Africa [1, 3, 8, 12, 18]. First recognized in South Korea in the early 2000s, DHAV-3 has undergone a dramatic global expansion, with Bayesian skyline plot analyses revealing a significant increase in effective population size beginning around 2005, followed by a resurgence in viral circulation after 2020 [3]. This expansion is likely driven by a combination of factors, including the lack of cross-protective immunity from DHAV-1 vaccines, the virus's high mutation rate, and its ability to infect multiple duck breeds (Pekin, Muscovy, Mallard, and Mullard) with varying pathogenicity [1, 3, 13].

The complete genome of DHAV-3 is approximately 7,690–7,769 nucleotides in length, sharing 91.9–99.9% nucleotide identity among strains but only approximately 74% identity with DHAV-1 [14, 18]. Phylogenetic analysis of the VP1 gene has revealed that DHAV-3 segregates into two major genotypes, designated GI and GII, with GI being the currently dominant genotype and further subdivided into multiple sublineages [3]. The GII genotype is characterized by a distinctive C-terminal insertion in VP1 (182T-183P-184M), which is predicted to alter the antigenic surface of the capsid and potentially enhance host adaptation [3]. This structural modification may underlie the ability of GII strains to evade immune responses elicited by GI-based vaccines.

The VP1 gene of DHAV-3 contains a single hypervariable region (HVR) with 10 amino acid mutations compared to the reference strain DHAV3/DN2/Vietnam/2011, and selection pressure analyses have identified 79 amino acid variation sites distributed across nine high-frequency mutation regions and six conserved functional domains [1, 3]. These data demonstrate a dynamic evolutionary balance between functional constraint, maintaining essential structural and receptor-binding properties, and adaptive flexibility that allows the virus to escape host immunity and expand its host range [3].

Importantly, DHAV-3 has been documented to cause disease in ducklings as old as 28 days of age, breaking the classical paradigm that DHAV primarily affects ducklings under one week of age [1]. This expanded age susceptibility, coupled with the virus's ability to replicate to high titers in the liver and induce severe hepatic necrosis, has profound implications for vaccination strategies and biosecurity protocols [12, 13]. The emergence of vaccine-escape strains, such as the HNAY2024 isolate from China, which carries eight unique amino acid substitutions across the polyprotein (V413M, E683Q, V855I, F892S, S1149I, T1151S, E1519G, and K1956E), further underscores the urgent need for updated genotype-matched vaccines [14].

DHAV Genotype 2: The Rare and Understudied Lineage

DHAV-2 is the least characterized and most rarely detected genotype among the three. First isolated in Taiwan, DHAV-2 has been reported in only a limited number of outbreaks, primarily in East Asia and, more recently, in India [2, 10]. The complete genome sequence of an Indian DHAV-2 isolate (OQ862826) was elucidated in 2025, revealing a genome of 7,769 nucleotides with a 5′ UTR of 653 nucleotides and a 3′ UTR of 366 nucleotides [2]. Phylogenetic analysis confirmed that the Indian isolate clusters with the two previously known Taiwanese DHAV-2 strains, exhibiting 93% nucleotide identity and 97.5% amino acid identity across the polyprotein [2].

Comparative genomic analysis of DHAV-2 with DHAV-1 and DHAV-3 has revealed distinct antigenic properties, particularly in the VP1 protein. Despite the overall genetic diversity, a highly conserved B-cell epitope (174LPSPTY179) has been identified across all three DHAV-2 strains, which is strikingly similar to the conserved LPAPTS motif in DHAV-1 [2, 6]. This conservation suggests that this epitope plays a critical functional role in virus-host interaction, potentially in receptor binding or entry, and may represent a target for pan-genotype vaccine development.

Perhaps the most clinically significant finding regarding DHAV-2 is the absence of serological cross-neutralization between DHAV-1 and DHAV-2 [2]. This complete lack of cross-protection has critical implications for vaccine development, as it indicates that monovalent vaccines against DHAV-1 will provide no protection against DHAV-2 infection. This antigenic independence reinforces the necessity of multivalent or genotype-specific vaccines, particularly in regions where multiple genotypes co-circulate.

Intratypic Diversity and the Complexities of Sub-Genotyping

While the three-genotype classification system remains the standard framework, accumulating evidence from whole-genome sequencing and comprehensive phylogenetic analyses has revealed substantial intratypic diversity that challenges simple taxonomic boundaries. Early studies based on codon usage bias and relative synonymous codon usage (RSCU) values identified three distinct genotypes (A, B, and C) among DHV isolates, with DHV-N strains from Taiwan, South Korea, and Mainland China clustering into genotypes A and B, while classical DHAV-1 isolates fell into genotype C [9]. This suggests that what we currently classify as a single genotype may, in fact, contain multiple divergent lineages with distinct evolutionary histories.

The identification of highly divergent DHAV-1-like strains from wild ducks in northeastern Siberia further complicates the taxonomic picture. These wild duck isolates share only 77.83% nucleotide identity and 89.68% amino acid identity with the most closely related DHAV-1 reference sequences, suggesting they represent a highly divergent lineage that may warrant sub-genotype or even new genotype classification [10]. The detection of DHAV in wild Anas crecca (Eurasian teal) highlights the role of wild waterfowl as potential reservoirs and vectors for viral dissemination, which has profound implications for disease surveillance and control.

In Egypt, the co-circulation of multiple genetic clusters within both DHAV-1 and DHAV-3 genotypes has been well documented. Egyptian DHAV-1 isolates have been shown to cluster into at least four distinct groups, with recent field strains falling into Group 4, while the commercial vaccine strains belong to Group 1 [16, 17, 19]. Similarly, DHAV-3 strains from Egypt cluster with Chinese and Korean-Vietnamese strains within different subgroups, exhibiting 92.4–93.7% amino acid identity to Asian reference strains but only 74.4% identity to the Egyptian DHAV-1 vaccine strain [1, 18]. This genetic divergence between circulating field strains and vaccine strains is a major driver of vaccine failure and disease outbreaks in vaccinated flocks.

The 5′ UTR as a Genotyping Target and Its Limitations

The 5′ UTR of the DHAV genome, which contains elements critical for translation initiation and replication, has proven to be a valuable target for both genotyping and differential detection of DHAV-1 and DHAV-3. Reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the 5′ UTR have been developed that can simultaneously detect and discriminate between DHAV-1 and DHAV-3 in a single reaction [5, 20]. These assays exploit conserved sequence differences between the two genotypes, with universal primers amplifying both genotypes and type-specific primers producing amplicons of different sizes (approximately 300 bp for DHAV-1 and approximately 400 bp for DHAV-3) [20].

The Centers for Disease Control and Prevention (CDC) and WOAH have endorsed the use of such molecular diagnostic tools for rapid outbreak response and surveillance, as they enable the identification of mixed infections and the monitoring of genotype shifts in real time. Clinical surveys using these assays have revealed that co-infections with DHAV-1 and DHAV-3 occur at rates of approximately 9–15% in some duck populations, highlighting the complexity of field epidemiology and the potential for recombination between genotypes [5, 20]. However, the 5′ UTR is highly conserved and may not capture the full extent of genetic diversity within a genotype, making it unsuitable for fine-scale phylogenetic analyses that require the more variable VP1 gene [22].

Host Range and Susceptibility Across Duck Breeds

The pathogenicity of DHAV genotypes varies significantly across different duck breeds, which has important implications for disease management and vaccine development. DHAV-3, in particular, has been shown to cause more severe disease in Pekin ducks (Anas platyrhynchos domesticus) compared to Muscovy ducks (Cairina moschata), with Pekin ducklings exhibiting higher viral shedding, more pronounced hepatic histopathological lesions, and greater elevations in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels [13]. Interestingly, Muscovy ducklings mounted a stronger interferon-β (IFN-β) and

Molecular Pathogenesis of Duck Hepatitis A Virus

Duck hepatitis A virus (DHAV), a member of the genus Avihepatovirus within the family Picornaviridae, is the primary etiological agent of duck viral hepatitis (DVH), an acute, highly contagious, and frequently fatal disease of young ducklings. The virus, officially classified as Avihepatovirus ahepati, exists as three distinct genotypes, DHAV-1, DHAV-2, and DHAV-3, which exhibit differential geographic distributions, antigenic properties, and pathogenic profiles [2, 10]. The molecular pathogenesis of DHAV is a multifaceted process governed by intricate virus–host interactions, encompassing specific viral genetic determinants of virulence, a dysregulated host innate immune response culminating in a profound cytokine storm, perturbation of hepatic metabolism, and the exploitation of host cellular machinery for replication. Understanding these molecular underpinnings is critical for deciphering the variable clinical outcomes observed across different duck breeds and ages, and for informing the development of effective countermeasures, including vaccines and antiviral strategies, against this economically significant pathogen recognized by the World Organisation for Animal Health (WOAH).

Viral Entry, Cellular Tropism, and Replication Dynamics

The initial step in DHAV pathogenesis is the attachment and entry into permissive host cells. While the precise cellular receptor(s) for DHAV remain largely uncharacterized, the virus exhibits a pronounced tropism for hepatocytes, the parenchymal cells of the liver, which represent the primary site of viral replication [12, 37]. The viral capsid, composed of the structural proteins VP0, VP3, and VP1, mediates this interaction. The VP1 protein is of paramount importance, serving as the major surface-exposed capsid protein and the principal target of neutralizing antibodies.

The viral life cycle, particularly replication kinetics, is a critical determinant of virulence and disease outcome. Comparative studies using DHAV-3 in duck embryo fibroblast (DEF) cells have revealed distinct growth characteristics between virulent and attenuated strains. The virulent C-GY strain of DHAV-3 was shown to replicate more rapidly and achieve peak viral loads earlier in the infection cycle compared to its attenuated counterpart, YDF120 [25]. This accelerated replication likely contributes to the overwhelming of early host defenses and the rapid onset of severe pathology in vivo. The ability to propagate productively in cell culture, even without overt cytopathic effects, underscores the fine balance between viral replication and host cell survival, a balance that is tipped towards cell destruction during fulminant in vivo infection.

The presence of inhibitory factors in biological sera, such as fetal calf serum (FCS), which can non-specifically inhibit DHAV adsorption, replication, and release, highlights the precarious nature of the virus' initial interaction with the host environment and suggests that in vivo susceptibility may be modulated by local humoral factors [25, 35]. This observation is a crucial reminder that molecular pathogenesis is not solely a function of the virus but is profoundly shaped by the host milieu at the site of infection.

Genetic Determinants of Virulence: The Central Role of VP1

A wealth of evidence points to the VP1 capsid protein as a pivotal molecular determinant of DHAV virulence, antigenicity, and host adaptation. The VP1 gene, in particular its carboxyl-terminal (C-terminal) region, exhibits a high degree of genetic plasticity, harboring hypervariable regions (HVRs) that are subject to intense selective pressure [1, 3, 8, 17]. These HVRs are thought to represent sites of immune recognition, and their variation is a primary mechanism for immune evasion.

Comparative analyses of virulent and attenuated DHAV-1 strains have identified specific amino acid substitutions within VP1 that correlate with changes in pathogenicity. For instance, several amino acid residues, such as V129, S142, L181, G184, and K217, have been associated with viral attenuation in Egyptian DHAV-1 isolates, while residues like N193 and E205 are found in virulent field strains, suggesting they are markers of a pathogenic phenotype [17, 19]. The critical nature of the C-terminal region is further emphasized by the identification of a conserved linear B-cell epitope, LPAPTS (DHAV-1) or its genotype-specific variant LPSPTY (DHAV-2), which is a target of neutralizing monoclonal antibodies [2, 6]. Mutations within or proximal to this epitope, such as the S178Y escape mutation identified in a virulent Egyptian DHAV-1 field isolate, can directly alter the antigenic landscape, potentially allowing the virus to circumvent vaccine-induced humoral immunity and establish a productive infection in vaccinated flocks [11].

For DHAV-3, a comprehensive structural and phylogenetic analysis of global VP1 sequences has defined two major genotypes (GⅠ and GⅡ). GⅠ is the currently dominant genotype, subdivided into multiple sublineages, while GⅡ strains are distinguished by a unique C-terminal insertion (182T-183P-184M) that is predicted to alter the surface topology of the capsid, potentially enhancing host adaptation and altering antigenicity [3]. The emergence of such structural changes underscores the continuous evolutionary arms race between the virus and the host's immune system. Furthermore, novel DHAV-3 strains with vaccine-escape potential, such as the Chinese isolate HNAY2024, have been shown to possess multiple amino acid substitutions across the polyprotein (e.g., V413M, E683Q, V855I), which are predicted to contribute to adaptive changes in viral antigenicity and replication fitness, enabling them to cause high mortality even in ducklings beyond the typical age of susceptibility [14].

The Host Response: A Double-Edged Sword of Innate Immunity and Cytokine Storm

The host's innate immune response is the first line of defense against DHAV infection. The virus is recognized by pattern recognition receptors (PRRs), most notably retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated protein 5 (MDA5), and Toll-like receptors (TLR4/7), which are upregulated in response to infection [21, 36]. These sensors initiate a signaling cascade leading to the production of type I interferons (IFN-α/β) and a broad array of pro-inflammatory cytokines. While this response is essential for controlling viral replication, a dysregulated and excessive immune reaction is the primary driver of the severe hepatic pathology seen in DVH.

Evidence demonstrates that the magnitude and balance of this response distinguish resistant from susceptible birds. In susceptible Pekin duck lines (e.g., Z8S2) infected with DHAV-3, a profoundly stronger and more rapid upregulation of PRRs and cytokines (IL-2, IL-6, IL-8, IFN-α, and IFN-γ) is observed in the liver compared to resistant lines, correlating with extremely high viral loads and mortality [36]. This exuberant response, rather than controlling the infection, paradoxically exacerbates liver damage. Proteomic analysis of DHAV-3-infected livers has identified 39 significantly up-regulated proteins, with many involved in the type I interferon signaling pathway. The interaction of these proteins appears to create a feedback loop that not only promotes viral genome replication but also amplifies the inflammatory response, leading to severe hepatitis [24]. This pathological hallmark, termed a "cytokine storm," is a critical feature of DHAV pathogenesis. The storm results in massive hepatocyte apoptosis, necrosis, hemorrhage, and bile duct hyperplasia, which are the characteristic histopathological lesions of DVH [26, 30].

The role of specific innate immune receptors in susceptibility is further highlighted by studies on the nucleotide-binding oligomerization domain-containing protein 1 (NOD1). NOD1, a cytosolic PRR, was found to be highly expressed in susceptible duck livers, and its expression level directly influenced the number of DHAV-3 genomic copies in primary duck hepatocytes, suggesting it may act as a susceptibility factor that facilitates viral replication or potentiates the inflammatory response [33].

Metabolic Dysregulation and Host Genetic Determinants of Resistance

DHAV infection dramatically perturbs host metabolic homeostasis, particularly in the liver. A consistent observation in susceptible birds is profound metabolic dysregulation, leading to hypoglycemia and dramatic elevations in serum liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are direct indicators of hepatocyte damage [13, 34, 36]. Transcriptomic analyses of resistant (Z8R) and susceptible (Z8S) Pekin ducks have revealed that DHAV-3 infection profoundly disrupts glucose metabolism in susceptible individuals. This hypoglycemia is not merely a consequence of liver failure but is mechanistically linked to the cytokine storm. Pro-inflammatory cytokines are proposed to activate signaling pathways like PI3K-AKT and JAK-STAT via upregulation of JAK2, which in turn downregulates key gluconeogenic enzymes such as G6PC and ACAT1, suppressing the liver's ability to synthesize glucose [34].

Lipid metabolism also plays a crucial role in the host's response. Host lipid profiling and transcriptomics have identified that pre-existing high levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) are associated with resistance to DHAV-3 infection in Pekin ducks [27]. This suggests that the host's basal metabolic state can predetermine susceptibility. The gene ACSL6, involved in fatty acid metabolism, was found to co-regulate distinct lipid metabolites, linking host genetics directly to the metabolic environment that either supports or suppresses viral replication [27].

The genetic basis for differential susceptibility is being unraveled through selective breeding programs and genomic analyses. Resistant (Z8) and susceptible (Z7) Pekin duck lines have been developed, exhibiting mortality rates as divergent as 7.8% and 81%, respectively [31]. Whole-genome analysis identified key selection signals. Susceptibility was linked to multiple mutations in the LRIG3 gene, while resistance was associated with a large number of mutations in the CRHR2 gene, which encodes a receptor involved in stress response and immune modulation [31]. Further transcriptomic studies pinpointed IFITM1 (interferon-induced transmembrane protein 1) as a key candidate gene. IFITM1, known to have broad antiviral activity through restricting viral fusion and entry, was found to be differentially expressed and capable of affecting the cell cycle in duck embryo fibroblasts upon DHAV-3 infection, providing a mechanistic link between innate immunity, cellular proliferation, and resistance [32].

The Role of RNA Editing in Pathogenesis

A more recently appreciated layer of complexity in DHAV pathogenesis is the role of RNA editing, a post-transcriptional modification that can alter RNA stability and protein sequences. During DHAV-3 infection, a dynamic landscape of RNA editing events is established in the host liver. Profiling of these events in susceptible and resistant ducklings identified thousands of differential RNA editing sites (DRESs). Intriguingly, editing events within the 3′-untranslated regions (UTRs) of host genes were predicted to cause the loss or gain of microRNA (miRNA) binding sites, thereby altering the expression of target genes critical for vesicle-mediated transport and immune pathways [28]. Additionally, some DRESs in coding sequences resulted in non-synonymous amino acid changes in host proteins vital for viral infection [28]. This suggests that DHAV may not only be a target of the host's RNA editing machinery but may also actively modulate this process to its advantage, creating an environment more permissive for replication.

Age-Dependent Susceptibility and the Gut-Liver Axis

A hallmark of DVH is the age-dependent susceptibility, with ducklings under three weeks of age being most vulnerable. This phenomenon is not solely due to an immature adaptive immune system but is also linked to the development of the intestinal microbiota and its interaction with hepatic immunity. Integrated analyses of the gut microbiome and liver transcriptome have revealed that the resistance to DHAV-3 increases with age and correlates with changes in the composition of ileal microbes, such as Candidatus Arthromitus, Bacteroides, and Enterococcus [29]. These age-related microbial shifts were significantly correlated with the expression of hepatic genes involved in immunity. Crucially, the IFIH1 (MDA5)-mediated induction of the interferon-alpha/beta pathway was identified as a central node connecting the gut microbiota to the host's antiviral state in the liver [29]. The presence of specific microbes at different ages appears to prime the liver's innate immune system, leading to differential production of CD8+ T cells and influencing the overall susceptibility to DHAV. This gut-liver axis adds another profound dimension to the molecular pathogenesis of the virus, highlighting that susceptibility is a systemic property influenced by the entire organism's developmental and microbial status.

Epidemiology and Global Distribution of DHAV Genotypes

The epidemiology of Duck Hepatitis A Virus (DHAV) represents a dynamic and economically consequential landscape, characterized by the differential geographic distribution, shifting predominance, and complex co-circulation of its three recognized genotypes: DHAV-1, DHAV-2, and DHAV-3. Understanding the global distribution of these genotypes is not merely an academic exercise; it is a critical prerequisite for designing effective vaccination strategies, conducting risk assessments for international trade, and anticipating future epizootic threats. The World Organisation for Animal Health (WOAH) recognizes duck viral hepatitis as a significant transboundary disease, underscoring the need for robust global surveillance. The available molecular epidemiological data, drawn from over six decades of observation, reveal a narrative of a classic, globally distributed pathogen (DHAV-1) being progressively challenged and, in many key production regions, supplanted by an emergent, more aggressive genotype (DHAV-3), while a third, enigmatic genotype (DHAV-2) remains confined to a very limited geographic range.

Historical Context and the Early Dominance of DHAV-1

For much of the 20th century, DHAV-1 was considered the sole etiological agent of duck viral hepatitis and was, therefore, globally ubiquitous wherever domestic ducks were raised intensively. First identified in the United States in 1945, DHAV-1 was subsequently reported across Europe, Asia, and Africa, establishing a pattern of widespread endemicity [12, 15]. The genetic diversity within DHAV-1 has been extensively characterized, revealing a complex evolutionary history. Phylogenetic analyses of the VP1 gene, a key determinant of antigenicity, have consistently demonstrated that DHAV-1 strains can be segregated into multiple genetic groups or sub-genotypes, reflecting their geographic origin and temporal evolution. For instance, studies have identified at least four distinct genetic groups among DHAV-1 strains circulating globally, with specific clades (e.g., Group 4) becoming dominant in regions like Egypt in recent years [16, 17]. The molecular clock analyses suggest that this global dissemination was facilitated by the expansion of commercial duck farming and the unrestricted movement of live birds and poultry products prior to the implementation of rigorous biosecurity measures.

Despite its global reach, DHAV-1 has not remained static. Continuous evolution, driven by the error-prone RNA-dependent RNA polymerase and positive selective pressure, has led to the emergence of antigenically distinct variants capable of evading vaccine-induced immunity. A hallmark study identified a unique escape mutation, S178Y, within a conserved B-cell epitope (LPAPTS) on the VP1 protein of a contemporary Egyptian DHAV-1 isolate [6, 11]. This mutation, which lies within a critical neutralizing antibody target, demonstrates the virus's capacity to alter its surface architecture to circumvent host immune responses, even in the face of widespread vaccination. The presence of such mutations, coupled with the identification of recombinant DHAV-1 strains in Egypt [16], highlights the ongoing evolutionary arms race between the virus and control measures. The efficacy of the widely used DHAV-1 live attenuated vaccines has thus become variable; while they may confer robust protection against homologous strains, their protective breadth against increasingly divergent field variants is demonstrably waning, with challenge studies showing survival rates dropping to as low as 40-60% against heterologous DHAV-1 strains [4].

The Emergence and Global Dissemination of DHAV-3: A Paradigm Shift

The most significant epidemiological shift in the history of DHAV has been the emergence and explosive global spread of DHAV-3. First recognized in South Korea and China in the late 1990s and early 2000s, DHAV-3 has, within two decades, transitioned from a localized novel pathogen to the dominant cause of duck viral hepatitis in East Asia and has established a major foothold in Africa [12, 19, 25]. The molecular drivers of this success are being actively elucidated. A comprehensive phylodynamic analysis of 79 amino acid variation sites across the VP1 gene of DHAV-3, based on a large global dataset, revealed that the virus is segregated into two major genetic lineages: Genotype I (GI) and Genotype II (GⅡ) [3]. GI is currently the globally dominant lineage and has undergone a remarkable population expansion beginning around 2005, followed by a resurgence in viral circulation after 2020 [3]. This expansion is not coincidental but is linked to specific molecular adaptations. Notably, GⅡ strains possess a distinctive C-terminal insertion (182T-183P-184M) in the VP1 protein, a region critical for receptor binding and antigenicity, which is predicted to alter viral tropism and enhance host adaptation [3].

The epidemiological trajectory of DHAV-3 provides a clear case study of viral emergence following a spillover event or a significant genetic leap. The first report of DHAV-3 outside of Asia came from Egypt in 2020, where it was detected in vaccinated flocks in the Nile Delta, co-circulating with the classic DHAV-1 [1]. This introduction was not a single event; subsequent surveillance in Egypt has shown that DHAV-3 has become the predominant genotype, accounting for the majority of outbreaks in commercial duck farms [18, 26]. For example, in one study, 18 out of 20 positive duck farms in North Egypt were infected with DHAV-3, while only two harbored DHAV-1 [1]. The phylogenetic analysis of these Egyptian DHAV-3 strains showed they clustered closely with Chinese and Korean-Vietnamese strains, suggesting a direct epidemiological link and a likely route of introduction via international trade or contaminated biological products [1, 18]. The virus has since been detected across multiple governorates, including Sharkia and Benha, demonstrating its capacity to rapidly establish endemicity in a naïve population [11, 18]. This rapid continental leap has been mirrored by the detection of highly divergent DHAV-1-like picornaviruses in wild ducks (Anas crecca) in Northeastern Siberia, indicating that the virus's host range and geographic distribution may be greater than previously assumed, with wild waterfowl potentially serving as reservoir hosts for novel lineages capable of seeding future outbreaks in domestic flocks [10].

DHAV-2: An Enigmatic and Spatially Constrained Genotype

In stark contrast to the global dissemination of DHAV-1 and DHAV-3, DHAV-2 remains the most geographically restricted and genetically enigmatic of the three genotypes. For decades, DHAV-2 was believed to be exclusively confined to the island of Taiwan, where it was first isolated and characterized [2, 9]. Its presence was considered a localized oddity, likely resulting from a unique evolutionary trajectory in geographic isolation. This paradigm was shattered by the first-ever report and complete genome sequencing of a DHAV-2 isolate from India in 2025 [2]. This isolate, recovered from ducklings in Tamil Nadu, represents a significant expansion of the known range of DHAV-2, demonstrating that the virus is not a Taiwanese endemicity but has a wider, albeit currently poorly understood, distribution in South Asia.

The molecular characterization of this Indian DHAV-2 strain (OQ862826) provides critical insights into its evolution. It shares 93% nucleotide identity and 97.5% amino acid identity with the two Taiwanese reference strains, indicating that despite significant geographic separation, the viruses share a common ancestry [2]. The conservation of a highly specific B-cell epitope (174LPSPTY179) in the VP1 protein across all known DHAV-2 strains is remarkable and suggests a conserved functional or structural requirement, even as other regions of the genome have diverged [2]. Critically, serological studies have confirmed a complete absence of cross-neutralization between DHAV-2 and DHAV-1 [2]. This profound antigenic independence has major implications for vaccine development; it means that the current global vaccine stock, which is entirely composed of DHAV-1 or DHAV-3 strains, would confer no protection against a DHAV-2 incursion. The sporadic detection of DHAV-2, with decades between isolations in Taiwan and the single report in India, raises fundamental questions about its true prevalence, reservoir host (perhaps a specific wild duck species), and transmission dynamics. It is possible that DHAV-2 circulates at a low level in a sylvatic cycle, only occasionally spilling over into domestic ducks, which would account for its rare detection.

Co-Circulation and the New Reality of Multi-Genotype Endemicity

The contemporary epidemiological reality in major duck-producing regions is one of multi-genotype co-circulation, a scenario that severely complicates disease control. In both China and Egypt, the two epicenters of DHAV research, DHAV-1 and DHAV-3 are now found to be co-circulating on the same farms and even infecting the same birds [5, 7]. In a study of 55 clinical samples from China, a one-tube RT-PCR assay designed to differentiate the genotypes revealed that 20% were DHAV-1, 45% were DHAV-3, and 9% were co-infections [5, 20]. This pattern of co-circulation and co-infection creates an ideal environment for genetic recombination, a phenomenon already documented for both DHAV-1 and DHAV-3, and which could lead to the emergence of chimeric viruses with unpredictable pathogenic and antigenic properties [14, 16]. The presence of both genotypes in a single bird imposes a dual selective pressure, potentially accelerating the evolution of immune escape.

The consequences of this epidemiological shift are profound for vaccine efficacy and the global duck industry. The current vaccination strategies, which largely rely on monovalent live attenuated vaccines (primarily DHAV-1), are demonstrably failing in the face of DHAV-3 dominance. In Egypt, where a DHAV-1 vaccine is used, multiple studies have documented that the circulating field strains of DHAV-3 are genetically and antigenically distinct from the vaccine strain, with amino acid identities as low as 74.4% for the VP1 gene [1, 18, 26]. This mismatch explains the continued outbreaks in vaccinated flocks. Furthermore, experimental evidence confirms that a DHAV-1 vaccine provides suboptimal cross-protection against heterologous DHAV-3 strains, with survival rates of only 40-60% in ducklings without maternal antibodies, while a DHAV-3 vaccine was able to confer complete cross-protection against both homologous and heterologous DHAV-3 strains [4]. This suggests that DHAV-3 may possess a more conserved immunogenic landscape, or that its VP1 protein presents a broader array of cross-reactive epitopes. The need for bivalent or multivalent vaccines has become urgent, and studies have already demonstrated the superior protective efficacy of an inactivated bivalent DHAV-1/DHAV-3 vaccine compared to its monovalent counterparts, with neutralization indices of 5.6 and 5.4 versus 5.0 and 4.7, respectively [7].

In conclusion, the global distribution of DHAV genotypes is not a static map but a dynamic landscape of shifting dominance. The historical hegemony of DHAV-1 has been broken by the rapid, phylodynamically-driven emergence and intercontinental spread of DHAV-3. The detection of DHAV-2 in India, far from its presumed Taiwanese refuge, suggests that our understanding of the virus's true geographic range is incomplete. The widespread co-circulation of DHAV-1 and DHAV-3, coupled with their demonstrated ability to recombine and escape vaccine-induced immunity, represents a clear and present danger to global duck production. Moving forward, international surveillance efforts, guided by bodies like the FAO and WOAH, must be intensified, focusing on molecular characterization of circulating strains to inform the development of next-generation, genotype-matched vaccines that can provide broad and durable protection against this evolving viral threat.

Genetic Diversity and Evolutionary Dynamics of DHAV

The genetic landscape of Duck Hepatitis A Virus (DHAV) is a tapestry woven from the threads of mutation, recombination, selection pressure, and host adaptation, resulting in a dynamic and continually evolving pathogen. As a member of the Picornaviridae family within the genus Avihepatovirus, DHAV exists as three distinct genotypes, DHAV-1, DHAV-2, and DHAV-3, each exhibiting a unique evolutionary trajectory and epidemiological footprint [2, 10]. Understanding the intricate mechanisms that drive this diversity is not merely an academic exercise; it is fundamental to predicting future outbreak patterns, assessing the durability of existing vaccines, and designing next-generation control strategies. The evolutionary dynamics of DHAV are characterized by a complex interplay between the virus's high mutation rate, its capacity for recombination, the selective pressures imposed by host immunity and vaccination, and the ecological factors governing its transmission across different duck populations and geographic regions.

Phylogeographic Diversification and the Emergence of Globally Significant Lineages

The historical and contemporary distribution of DHAV genotypes reveals a tale of viral emergence, geographic expansion, and lineage displacement. DHAV-1, the classic serotype first identified in 1945, was for decades the predominant cause of duck viral hepatitis (DVH) globally, particularly in the United States and parts of Asia [15]. However, the latter half of the 20th century witnessed a critical shift, with DHAV-3 emerging as the dominant genotype in East and South Asia, the world's primary duck-producing regions, since the early 2000s [3, 12, 24, 25]. This displacement is not merely a geographic curiosity; it represents a fundamental change in the viral ecosystem, driven by the superior fitness of DHAV-3 in naïve duck populations and its ability to circumvent immunity generated by DHAV-1-based vaccines.

The phylogeographic dynamics of DHAV-3 have been comprehensively studied through analyses of its VP1 gene, revealing a classification into two major genotypes, GⅠ and GⅡ [3]. GⅠ is currently the globally dominant genotype and has undergone significant intra-genotypic radiation, splitting into multiple sublineages that are dispersed across East Asia, Southeast Asia, and, more recently, Africa [3, 8]. A major demographic expansion of the DHAV-3 population was identified using Bayesian skyline plot analysis, beginning around 2005, corresponding to the intensification of duck farming and the implementation of sub-optimal vaccination strategies in many Asian countries [3]. Crucially, this analysis also detected a resurgence in viral circulation after 2020, a worrying sign that suggests ongoing evolutionary adaptation and sustained epidemiological threat [3]. The first detection of DHAV-3 outside of Asia occurred in Egypt between 2016 and 2019, as reported in multiple studies [1, 18, 26]. Phylogenetic analyses of Egyptian DHAV-3 strains consistently show them clustering with Chinese, Korean, and Vietnamese strains, indicating multiple independent introductions, likely through the international movement of duck stock or contaminated fomites [1, 16, 26]. The Egyptian isolates form a distinct cluster within the broader Asian lineages, suggesting that once introduced, the virus has undergone local adaptation and independent evolution in the novel North African ecological context [18].

DHAV-2, meanwhile, has historically been a cryptic genotype, with only a few isolates reported from Taiwan and, more recently, India [2]. The comprehensive genomic characterization of an Indian DHAV-2 isolate (OQ862826) provided a critical evolutionary reference point, showing approximately 93% nucleotide identity and 97.5% amino acid identity with the Taiwanese strains [2]. This level of divergence, while clearly placing it within DHAV-2, also reveals that a reservoir of genetic variability exists within this genotype that is poorly sampled. The absence of serological cross-neutralization between DHAV-1, DHAV-2, and DHAV-3 underscores the antigenic independence of these evolutionary lineages, a fact with profound implications for vaccine design [2, 4]. Furthermore, the recent isolation from wild ducks (Anas crecca) in Northeastern Siberia of a highly divergent DHAV-1-like picornavirus, sharing only 77.83% nucleotide identity in its polyprotein gene, hints at an even greater, unsampled genetic diversity within the Avihepatovirus genus [10]. This finding introduces a critical wild-bird reservoir component into the evolutionary equation, suggesting that future genotype emergence may not be limited to domestic duck populations.

The VP1 Gene: An Evolutionary Hotspot for Antigenic Drift and Host Adaptation

The VP1 capsid protein is the primary target of neutralizing antibodies in the duck host and, consequently, is subject to intense selective pressure from the host immune system [3, 6, 8]. This pressure makes the VP1 gene a veritable evolutionary hotspot, where mutation, selection, and structural adaptation converge to drive antigenic diversity. A comprehensive analysis of a global dataset of DHAV-3 VP1 sequences identified 79 amino acid variation sites, distributed across nine high-frequency mutation regions and six conserved functional domains [3]. This pattern reflects a delicate evolutionary balance: the virus must maintain the structural integrity of conserved domains essential for capsid assembly and receptor binding while simultaneously permitting variation in surface-exposed loops to evade antibody neutralization.

Among the most significant structural features identified is a distinctive C-terminal insertion of three amino acids (182T-183P-184M) present in the GⅡ genotype of DHAV-3 [3]. This insertion is predicted to alter the surface topology of the VP1 protein, potentially modifying the antigenic landscape and enhancing host adaptation. This motif is absent in GⅠ strains, providing a clear molecular marker for lineage differentiation and a potential target for genotype-specific diagnostics. The C-terminus of VP1 is also the locus of a hypervariable region (HVR) that has been extensively characterized in both DHAV-1 and DHAV-3 [1, 8]. In Egyptian DHAV-3 strains, this HVR exhibited 10 amino acid mutations compared to a reference Vietnamese strain [1]. For DHAV-1, three distinct HVRs have been identified, with the carboxyl-terminal region showing particular dynamism. Mutations such as I180T, G184E, D193N, and M213I in the VP1 C-terminus were identified in Egyptian DHAV-1 field isolates, along with a deletion mutation at I189 [17]. These changes are directly implicated in modulating virulence and host range. Specifically, residues N193 and E205 are consistently found in virulent DHAV-1 strains, while residues L181, G184, and K217 are linked to attenuation [19, 23]. The accumulation of such mutations in field strains circulating despite vaccination programs strongly suggests ongoing antigenic drift, whereby the virus evolves to escape vaccine-induced antibodies [4].

The identification of a highly conserved linear B-cell epitope, LPAPTS (corresponding to residues 173-178 in DHAV-1 VP1), was a landmark discovery [6]. This epitope is recognized by a neutralizing monoclonal antibody (mAb 2D10) and is conserved across DHAV-1 genotypes, suggesting it is a critical functional site for host antibody binding. However, the subsequent observation of an escape mutation, S178Y, in an Egyptian DHAV-1 field isolate [11] provides direct molecular evidence that this epitope is under active selection. The S178Y substitution, while apparently rare, demonstrates the virus's capacity to alter even conserved, functionally important sites under the selective pressure of a host immune response primed by vaccination or prior infection. For DHAV-3, the conservation of a similar B-cell epitope (174LPSPTY179) in the VP1 protein of all three known DHAV-2 strains [2] and across DHAV-3 [3] suggests that while the exact sequence may differ, the region serves a universal immunogenic function. This conservation within a hypervariable background offers a potential target for a broadly protective multi-epitope vaccine, as recently explored using immunoinformatics and experimental validation [38].

Recombination as a Driver of Genomic Innovation and Lineage Evolution

Beyond the incremental changes of point mutation, recombination serves as a powerful evolutionary force that can rapidly generate new genomic configurations, allowing DHAV to explore fitness landscapes that would be inaccessible through gradual mutation alone. The picornavirus genome, with its single-stranded positive-sense RNA and modular organization, is particularly prone to recombination events during RNA replication. Compelling evidence for the role of recombination in DHAV evolution emerged from a comprehensive genomic study of Egyptian DHAV-1 strains [16]. Recombination analysis revealed the emergence of a new recombinant virus, DHAV-1 strain Egypt-10/2019, which arose from the mixing of genetic material from distinct parental lineages. This event demonstrates that co-infection of a single duck with two different DHAV-1 strains, or potentially with DHAV-1 and another picornavirus, can lead to the generation of a novel chimeric virus with unpredictable biological properties.

The evolutionary significance of this is profound. Recombination can introduce new combinations of structural and non-structural proteins, potentially leading to viruses with altered tissue tropism, increased virulence, or enhanced replicative fitness. It can also facilitate the rapid spread of adaptive mutations across different genetic backgrounds. The selective pressure analyses performed on the Egypt-10/2019 strain and other Egyptian isolates further highlighted the importance of natural selection, identifying positive selection scores within or near areas associated with viral attachment and related functions [16]. This indicates that the newly generated recombinant genomes are then subject to purifying or directional selection, which refines their fitness within the host and population. This dynamic interplay between recombination and selection allows DHAV to adapt rapidly to changing environments, such as the introduction of new duck breeds, shifts in husbandry practices, or the widespread use of genotype-specific vaccines.

Host-Pathogen Co-Evolution and the Genetic Basis of Resistance and Susceptibility

The evolutionary trajectory of DHAV is not determined solely by the virus; it is profoundly shaped by the genetics of its duck host. The observation that some Pekin duck lines exhibit remarkable resistance to DHAV-3 while others are highly susceptible has provided a powerful natural system for studying host-pathogen co-evolution. Through selective breeding, researchers have established resistant (Z8R) and susceptible (Z7S and Z8S) Pekin duck lines, with mortality rates diverging to as low as 2.67% in resistant families and as high as 81% in susceptible families [31, 36]. This dramatic phenotypic difference has a clear genetic basis.

Comparative genomic analyses have identified key candidate genes associated with resistance and susceptibility. In resistant lines, the CRHR2 gene on chromosome 2 was identified as a major selection target, with 134 mutations accumulating in the resistant population [31]. The CRHR2 gene is involved in the stress response and immune regulation, suggesting that resistant ducks may have an inherently different capacity to modulate the inflammatory response to infection. Conversely, in susceptible lines, selection targeted the LRIG3 gene on chromosome 1, a gene involved in cell growth and differentiation, with 17 identified mutations [31]. Further fine-mapping and transcriptomic analyses pinpointed the NOD1 gene, a key innate immune sensor, as being strongly associated with DHAV-3 susceptibility [33]. Higher expression of NOD1 in susceptible ducks was correlated with increased viral genomic copies in the liver, and functional experiments in primary duck hepatocytes demonstrated that modulating NOD1 expression directly influenced DHAV-3 replication [33].

The link between host genetics and viral dynamics extends to cellular processes such as the cell cycle and lipid metabolism. The IFITM1 gene, an interferon-induced transmembrane protein known to restrict a wide range of viruses, was identified as a key candidate in the differential resistance to DHAV-3 [32]. Flow cytometry experiments revealed that the expression level of IFITM1 affected the cell cycle of duck embryo fibroblast cells after DHAV-3 infection, suggesting that the resistant line may limit viral replication by arresting cell cycle progression. Intriguingly, host lipid metabolism also plays a decisive role. Resistant ducks were found to have significantly higher baseline levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) than susceptible ducks [27]. Lipidomics and transcriptomics revealed that the ACSL6 gene, involved in fatty acid metabolism, co-regulates hepatic lipid pathways that are crucial for antiviral activity. This suggests that the host's metabolic state is not a passive bystander but an active determinant of viral evolutionary success. Viruses that can subvert host lipid droplets or membranes for replication factories may face a less permissive environment in ducks with a particular lipid profile.

Ecological and Temporal Dynamics Influencing Viral Evolution

The evolutionary dynamics of DHAV are inextricably linked to ecological and temporal factors that modulate the host-pathogen interaction. The age of the duckling at the time of infection is a critical determinant of disease outcome and, consequently, of the selective pressure on the virus. Younger ducklings, particularly those under 7 days of age, are exquisitely susceptible, with mortality rates approaching 100% for highly virulent strains. As ducks age, they develop increasing resistance, with the transition occurring around 14-21 days of age [29]. This age-dependent susceptibility is driven by the maturation of the immune system and, importantly, by the establishment of a stable intestinal microbiota. 16S rRNA sequencing and transcriptomics revealed that the ileal microbial composition changes with age, and that microbes such as Candidatus Arthromitus and Bacteroides are differentially abundant in younger, more susceptible ducklings [29]. The interaction between the gut microbiota and the host immune system, particularly through the IFIH1-mediated induction of the interferon-alpha/beta pathway, is a key regulator of antiviral immunity. This implies that viruses that evolve to infect and replicate in very young ducklings must contend with a different innate immune environment compared to those that successfully infect older birds.

Furthermore, the role of maternal-derived antibodies (MDA) adds another layer of selective pressure. High levels of MDA from vaccinated breeder flocks can protect day-old ducklings, but they also create a strong selective bottleneck. Only virus variants capable of escaping pre-existing antibodies, the "escape mutants", can establish infection in these MDA-positive ducklings [4]. This dynamic is perfectly illustrated by the vaccine challenge study, where DHAV-1 vaccines provided only 40-60% protection against heterologous strains in MDA-negative ducklings but required an additional vaccination at day-old to achieve full protection in MDA-positive birds [4]. This scenario actively selects for antigenically divergent variants, accelerating the pace of viral evolution. The concurrent circulation of DHAV-1 and DHAV-3 in many regions, along with the detection of co-infections [5, 20], provides the raw material for recombination and genetic exchange, ensuring a constant supply of genetic variation on which natural selection can act. The dual circulation of these genotypes in Egypt [1, 26], South Korea [4], and Vietnam [8] highlights the ongoing evolutionary arms race between the virus and its host, a race that is continually influenced by the ecological landscape of modern duck farming.

Molecular Diagnostics and Genotyping Methods for DHAV

The accurate and timely identification of Duck Hepatitis A Virus (DHAV) and its constituent genotypes is paramount for effective disease management, epidemiological surveillance, and the implementation of targeted control strategies. Given the significant economic losses inflicted upon the global duck industry by DHAV-1, DHAV-2, and DHAV-3, and the documented co-circulation of multiple genotypes within single geographic regions [1, 26], the development and refinement of robust molecular diagnostic tools have been a central focus of veterinary research. The World Organisation for Animal Health (WOAH) recognizes the importance of rapid and specific diagnostic methods for the control of notifiable diseases, and the methodologies developed for DHAV serve as a critical component of national surveillance programs. This section provides an exhaustive analysis of the molecular diagnostics and genotyping methods employed for DHAV, from foundational reverse transcription-polymerase chain reaction (RT-PCR) techniques to advanced next-generation sequencing (NGS) and immunoinformatics-driven approaches.

Foundational Molecular Detection: RT-PCR and Its Variants

The cornerstone of DHAV molecular diagnostics is the reverse transcription-polymerase chain reaction (RT-PCR), which enables the amplification of specific viral RNA sequences from clinical samples, most commonly liver tissue, but also from sera, feces, and allantoic fluid [1, 8, 11, 18]. The choice of genomic target region is critical, as it dictates the assay's sensitivity, specificity, and ability to differentiate between genotypes.

Targeting Conserved and Variable Genomic Regions

Early diagnostic efforts often targeted the highly conserved 3D gene, which encodes the RNA-dependent RNA polymerase (RdRp). This region is essential for viral replication and is present across all picornaviruses, making it a reliable target for pan-DHAV detection. Studies in Egypt, for instance, successfully employed RT-PCR targeting the 3D gene to screen duckling flocks, identifying a 50% positivity rate and confirming the circulation of DHAV-1 [19, 40]. However, while the 3D gene is excellent for initial detection, its high conservation limits its utility for genotyping, as sequence divergence between DHAV-1, DHAV-2, and DHAV-3 may be insufficient for definitive classification [18].

To achieve genotypic discrimination, researchers have increasingly focused on the VP1 gene, a major structural protein that forms the outer capsid and is a primary target for neutralizing antibodies. The VP1 gene contains hypervariable regions (HVRs) that are subject to significant genetic drift and positive selection pressure, making it an ideal phylogenetic marker [1, 3, 8, 16]. For example, phylogenetic analysis of the full-length VP1 gene has been instrumental in classifying DHAV-3 into two major genotypes (GⅠ and GⅡ) and multiple sublineages, revealing a complex evolutionary landscape driven by VP1 variation [3]. Similarly, the 5' untranslated region (5' UTR) and 3' UTR have been employed for typing, as they contain conserved structural elements essential for translation and replication but also harbor genotype-specific motifs [1, 20]. The 5' UTR, in particular, has been exploited for the design of type-specific primers due to its high degree of conservation within a genotype and variability between genotypes [5, 20].

One-Tube and Duplex RT-PCR for Simultaneous Detection and Typing

A major advancement in DHAV diagnostics has been the development of multiplex RT-PCR assays that can simultaneously detect and differentiate between co-circulating genotypes in a single reaction. This is particularly valuable in regions like Egypt, China, and Vietnam, where DHAV-1 and DHAV-3 are known to co-exist and even cause co-infections in individual ducklings [1, 5, 8, 20].

Chen et al. (2019) described a highly efficient one-tube RT-PCR method based on multiple alignments of the 5' NCR. By designing a universal forward primer and two genotype-specific reverse primers, they were able to amplify distinct amplicon sizes for DHAV-1 (approximately 400 bp) and DHAV-3 (approximately 200 bp) [5, 20]. This assay demonstrated remarkable robustness, successfully amplifying reference strains isolated over 60 years from diverse geographic locations, confirming the complete conservation of the primer binding sites. The assay's sensitivity was determined to be 10 pg of viral RNA, and it showed no cross-reactivity with other common duck-origin RNA viruses, such as avian influenza virus (AIV) or Newcastle disease virus (NDV) [20]. In a field application involving 55 clinical samples, this method detected 20% DHAV-1, 45% DHAV-3, and a notable 9% co-infection rate, underscoring the practical utility of this approach for routine surveillance [5, 20].

Building on this concept, Wen et al. (2014) established a genotype-specific one-step duplex RT-PCR that amplified the complete VP1 gene of DHAV-1 and DHAV-3. This approach not only allowed for simultaneous detection and differentiation but also provided full-length VP1 amplicons suitable for downstream sequencing and phylogenetic analysis. This dual functionality, diagnostic typing and generation of material for molecular epidemiology, makes this method particularly powerful for understanding the evolution and spread of field strains [22].

Advanced Genotyping and Molecular Characterization

While RT-PCR provides rapid genotyping, a deeper understanding of viral evolution, antigenic diversity, and pathogenesis requires more sophisticated molecular characterization techniques, including sequencing and phylogenetic analysis.

Sanger Sequencing and Phylogenetic Analysis

Sanger sequencing of PCR amplicons, particularly the VP1 gene, remains the gold standard for definitive genotyping and detailed genetic characterization. The resulting nucleotide and deduced amino acid sequences are subjected to phylogenetic analysis using algorithms such as Maximum Likelihood or Bayesian inference. This approach has been instrumental in:

• Confirming Genotype: Phylogenetic trees clearly cluster unknown isolates with reference strains of DHAV-1, DHAV-2, or DHAV-3, providing unambiguous genotyping [2, 8, 18].
• Identifying Sub-lineages and Variants: Within a genotype, phylogenetic analysis can reveal distinct sub-clades or genetic groups. For example, Egyptian DHAV-1 strains have been classified into multiple genetic groups (e.g., Group 1, Group 4, subclade B2), often correlating with geographic origin and time of isolation [16, 17, 19]. Similarly, DHAV-3 strains from Egypt have been shown to cluster separately from Asian strains, suggesting independent introduction and evolution [1, 18].
• Detecting Recombination Events: Recombination is a significant driver of picornavirus evolution. By analyzing incongruent phylogenetic signals between different genomic regions (e.g., VP1 vs. 3D), researchers can identify potential recombinant strains. Rohaim et al. (2021) reported the emergence of a recombinant DHAV-1 strain in Egypt, highlighting the role of recombination in generating genetic diversity [16].
• Mapping Amino Acid Substitutions: Sequence alignment allows for the identification of specific amino acid changes that may be associated with virulence, attenuation, or antigenic escape. For instance, specific residues in the C-terminus of VP1 (e.g., I180T, G184E, D193N, M213I) have been linked to virulence in Egyptian DHAV-1 strains [17]. The identification of a unique S178Y escape mutation in the VP1 of a DHAV-1 field isolate in Egypt, which was associated with reduced cross-neutralization by vaccine-induced antibodies, underscores the importance of continuous molecular surveillance [11].

Next-Generation Sequencing (NGS) for Whole-Genome Analysis

The advent of next-generation sequencing (NGS) has revolutionized the field of viral genomics, enabling the rapid and cost-effective determination of complete viral genomes. For DHAV, NGS provides an unprecedented level of detail, allowing for comprehensive analysis of all genomic regions, including the 5' and 3' UTRs, the entire polyprotein open reading frame, and the identification of minor variant populations (quasispecies).

The first complete genome sequence of a DHAV-2 isolate from India was recently obtained using NGS, revealing a genome of 7,769 bp and providing critical insights into its genome organization, protease cleavage sites, and conserved functional domains [2]. This level of detail is impossible to achieve with partial gene sequencing alone. Similarly, the complete genome of a DHAV-1 strain from Egypt (Du/Egy/Benha/2020/DHAV-1) was sequenced using NGS, revealing a 99.9% identity to a Hungarian strain from 2004 and highlighting the potential for long-distance viral spread [11]. NGS is also crucial for characterizing novel or highly divergent strains. Dubovitskiy et al. (2025) used a metagenomic approach to identify and sequence the complete genomes of two novel picornaviruses from wild ducks in Siberia, one of which was related to DHAV-1 but shared only 77.83% nucleotide identity, suggesting it represents a highly divergent lineage [10]. This demonstrates the power of NGS for discovering emerging pathogens and understanding the full diversity of the Avihepatovirus genus.

Immunoinformatics and Serological Correlates of Genotyping

Beyond direct viral RNA detection, molecular diagnostics are increasingly integrated with immunoinformatics to predict antigenic properties and inform vaccine design. The identification of conserved and variable B-cell and T-cell epitopes across DHAV genotypes is a critical application of these methods.

Epitope Mapping and Cross-Reactivity

Monoclonal antibodies (mAbs) have been used to precisely map linear B-cell epitopes on the VP1 protein. Wu et al. (2015) identified a highly conserved B-cell epitope, ¹⁷³LPAPTS¹⁷⁸, on the VP1 of DHAV-1 using a neutralizing mAb (2D10). This epitope was found to be conserved across DHAV-1 strains, suggesting its potential as a target for diagnostic assays or epitope-based vaccines [6]. Interestingly, a similar conserved B-cell epitope (¹⁷⁴LPSPTY¹⁷⁹) was identified in all three DHAV-2 strains, indicating a degree of structural conservation across genotypes despite significant sequence divergence in other regions of VP1 [2].

Conversely, the identification of genotype-specific epitopes is equally important. The hypervariable regions of VP1, particularly the C-terminal insertion (182T-183P-184M) found in DHAV-3 GⅡ strains, are predicted to be major antigenic determinants that differentiate genotypes and may drive serotype-specific immune responses [3]. This knowledge is being leveraged to design multi-epitope vaccines. Yang et al. (2025) used immunoinformatics to systematically identify linear B-cell, cytotoxic T-cell (CTL), and helper T-cell (HTL) epitopes from DHAV-1, DHAV-2, and DHAV-3. They constructed a chimeric multi-epitope vaccine candidate that was predicted to be highly immunogenic and cross-reactive. Preliminary experimental validation showed that the vaccine candidate induced high-titer antibodies (up to 1:128,000) in immunized animals, and the immune serum showed strong reactivity with recombinant VP proteins from all three genotypes, confirming the cross-reactive potential of the designed epitopes [38].

Virus Neutralization Tests (VNT) as a Functional Genotyping Tool

While molecular methods detect the genetic material of the virus, virus neutralization tests (VNT) provide a functional assessment of antigenic relatedness. VNT measures the ability of antibodies (from sera or mAbs) to neutralize viral infectivity, typically in cell culture or embryonated eggs. This assay is the gold standard for defining serotypes. The lack of serological cross-neutralization between DHAV-1 and DHAV-2, as demonstrated by Rajendran et al. (2025), provides the functional basis for their classification as distinct genotypes [2]. Similarly, VNT has been used to evaluate the antigenic distance between field isolates and vaccine strains. Moharam et al. (2025) used a cross-neutralization assay to assess the antigenic diversity between a newly isolated DHAV-1 field strain and the locally used live attenuated vaccine strain. The results revealed minimal antigenic variation, suggesting that the current vaccine remained effective against that particular field strain [11]. However, the same study also identified a unique escape mutation (S178Y) in the field strain, highlighting the potential for future antigenic drift that could be detected by VNT. In Egypt, VNT has been used to quantify the neutralizing indices (NIs) of bivalent and monovalent inactivated vaccines, demonstrating that a bivalent DHAV-1 + DHAV-3 vaccine elicited higher NIs (5.6 and 5.4) compared to monovalent vaccines (5.0 and 4.7), providing a functional correlate of the broader protection offered by multivalent formulations [7].

Diagnostic Challenges and Future Directions

Despite the powerful arsenal of molecular tools, several challenges remain. The high genetic diversity of DHAV, particularly the rapid evolution of the VP1 gene, necessitates continuous monitoring to ensure that diagnostic primers and probes remain effective against emerging variant strains [3, 4]. The discovery of highly divergent DHAV-like viruses in wild ducks [10] suggests that the current classification system may need to be expanded, and diagnostic assays must be designed to detect these novel lineages. Furthermore, the co-circulation of multiple genotypes and the occurrence of mixed infections [5, 20] require multiplex assays that can accurately quantify the relative abundance of each genotype in a single sample.

Future directions for DHAV diagnostics will likely involve the wider adoption of real-time RT-PCR (RT-qPCR) for quantitative viral load determination, which is crucial for understanding pathogenesis and evaluating vaccine efficacy [25, 39]. The development of isothermal amplification methods, such as loop-mediated isothermal amplification (LAMP), could provide rapid, point-of-care diagnostics that are accessible in low-resource settings. Finally, the integration of NGS into routine surveillance programs will be essential for tracking the emergence of new genotypes, identifying recombination events, and monitoring antigenic drift, thereby informing the timely update of vaccines and diagnostic protocols. The continued refinement of these molecular and immunological methods is not merely an academic exercise but a critical necessity for safeguarding the global duck industry against this ever-evolving pathogen.

Vaccine Development and Immune Evasion Challenges

The development of effective vaccines against Duck Hepatitis A Virus (DHAV) is fraught with complex immunological, virological, and epidemiological obstacles, primarily driven by the pronounced genetic and antigenic diversity across the three recognized genotypes and the emergence of variant strains capable of circumventing established immunity. The persistent failure of monovalent vaccines, particularly those based solely on DHAV-1, to confer cross-protection against DHAV-3 and, in some cases, against divergent DHAV-1 field strains, necessitates a profound re-evaluation of current vaccination strategies [1, 4]. The challenges are not merely academic; they represent a tangible and escalating threat to the global duck industry, as documented by the World Organisation for Animal Health (WOAH) and regional veterinary authorities, underscoring the urgent need for next-generation vaccine platforms that can outpace the virus’s evolutionary trajectory.

The Central Conundrum of Genotypic Divergence and Antigenic Mismatch

The paramount obstacle to universal DHAV control is the profound antigenic divergence between the three genotypes. DHAV-1, the historically dominant genotype, and DHAV-3, which has become the primary etiological agent in East Asia and has recently disseminated into Africa, share less than 75% amino acid identity in the critical VP1 capsid protein [1, 18]. This genetic chasm translates directly into immunological phenotype. Comparative analyses of VP1 sequences have revealed that DHAV-3 possesses a unique hypervariable region (HVR) with multiple amino acid substitutions compared to DHAV-1 vaccine strains, and critically, the classical DHAV-1 B-cell epitope (¹⁷³LPAPTS¹⁷⁸) is not fully conserved or is structurally presented differently in DHAV-3 [1, 6]. Consequently, vaccination with a DHAV-1 live attenuated vaccine, as is standard practice in many regions including Egypt and parts of Asia, fails to induce a neutralizing antibody response capable of effectively clearing a DHAV-3 challenge [1, 26]. This was starkly demonstrated in Egyptian duck farms, where despite routine vaccination, DHAV-3 was detected as the dominant genotype in outbreak samples, with the circulating field strains being genetically distant from the vaccine strain [1, 18]. Formal challenge trials have quantified this vulnerability, showing that DHAV-1 vaccines provide only 40-60% survival against heterologous DHAV-3 strains in ducklings without maternal antibodies, whereas a DHAV-3 vaccine provides complete cross-protection against both homologous and heterologous strains [4]. This data strongly supports the conclusion that the current vaccine landscape is inadequate and that genotype-matched vaccines, or ideally, multivalent formulations, are an absolute requirement for effective prophylaxis.

Molecular Mechanisms of Immune Evasion: Beyond Simple Sequence Divergence

Immune evasion by DHAV is not a monolithic phenomenon but a multifaceted strategy involving antigenic drift, epitope masking, and structural alterations in key capsid proteins, with the VP1 protein serving as the primary nexus of this evolutionary arms race. The VP1 protein is the major immunodominant antigen and the primary target of neutralizing antibodies, making it a hotspot for mutations that confer selective advantage under immune pressure [3, 6, 11]. Detailed structural and phylogenetic analyses of DHAV-3 VP1 have revealed a distinctive C-terminal insertion (¹⁸²T-¹⁸³P-¹⁸⁴M) in certain sublineages (GⅡ) that is predicted to underlie altered antigenicity and enhanced host adaptation, potentially by modifying the surface topology of the capsid and occluding conserved antibody binding sites [3]. This is consistent with observations that amino acid substitutions at the carboxyl-terminal of VP1, such as I180T, G184E, D193N, and M213I in DHAV-1, are associated with increased virulence and altered pathogenicity in experimentally infected Pekin and Muscovy ducklings [17].

Beyond escape from humoral immunity, emerging evidence points to viral strategies that subvert the host’s intrinsic and innate antiviral defenses. The host type I interferon (IFN) response is a critical first line of defense, and DHAV-3 infection has been shown to profoundly dysregulate this pathway. Proteomics analysis has revealed that DHAV-3 infection in Pekin ducks induces a significant upregulation of proteins involved in the RIG-I-like, Toll-like, and NOD-like receptor signaling pathways, with a notable interaction network of 11 upregulated proteins that paradoxically promotes interferon-induced protein synthesis while simultaneously supporting viral genome replication [24]. This suggests a sophisticated mechanism where the virus hijacks the host’s translational machinery to its own advantage, a process that can ultimately precipitate an uncontrollable inflammatory response and severe liver damage [24]. Furthermore, the NOD1 receptor has been identified as a key host factor associated with susceptibility; its overexpression in susceptible duck lines correlates with increased viral loads, indicating that DHAV may exploit this receptor for cellular entry or replication, effectively turning a host defense sensor into a viral accomplice [33]. The virus also appears to commandeer host cell cycle machinery, as the interferon-induced transmembrane protein 1 (IFITM1), typically a potent antiviral restriction factor, is differentially expressed between resistant and susceptible duck lines, and its modulation is linked to DHAV-3-induced cell cycle changes in duck embryo fibroblast cells [32]. This intricate interplay of innate immune modulation and host factor exploitation represents a sophisticated immune evasion strategy that extends well beyond simple antigenic variation.

The Dual Burden of Co-Circulation and Recombination

The epidemiological reality of DHAV is increasingly defined by the simultaneous circulation of multiple genotypes within the same geographic regions and even within the same host, creating a fertile ground for recombination and the emergence of novel, potentially vaccine-escaping chimeric viruses. In Egypt, recent surveillance has documented the co-circulation of DHAV-1 and DHAV-3 in the same pekin duck flocks, with DHAV-3 becoming the predominant genotype in commercial settings that rely on a DHAV-1 vaccine [1, 26]. Similarly, in China and Vietnam, co-infection of ducklings with DHAV-1 and DHAV-3 is now a frequently reported phenomenon, detected at rates of 9% or higher in clinical samples using specific multiplex RT-PCR assays [5, 20]. This genetic mixing bowl is of paramount concern because co-infection provides the necessary conditions for homologous recombination, a well-documented mechanism of genetic exchange in picornaviruses. The complete genome sequencing of Egyptian DHAV-1 isolates has already provided direct evidence of recombination events, where a field strain (Egypt-10/2019) emerged as a recombinant virus, highlighting the dynamic evolution of viral populations under the selective pressure of vaccination [16]. The potential for such recombination to shuffle antigenic determinants, creating a virus that combines the structural proteins of one genotype with the replication machinery of another, poses a dire threat to vaccine efficacy. A vaccine designed against a parental genotype may be rendered ineffective against a recombinant offspring that presents a novel antigenic mosaic. This underscores the critical need for robust, continuous genomic surveillance, as recommended by the FAO and WOAH, to monitor the emergence of such novel strains and rapidly adapt vaccine formulations.

Variable Vaccine Efficacy and Host-Specific Responses

Compounding the challenges posed by viral diversity is the variable protective efficacy of existing vaccines, which is modulated by host factors such as breed, age, and the presence of maternal-derived antibodies (MDA). Live attenuated DHAV-1 and DHAV-3 vaccines, while widely used, exhibit demonstrable shortcomings. Challenge trials in ducklings without MDA have shown that the DHAV-1 vaccine provides complete protection only against homologous strains by 4 days post-vaccination, but against heterologous DHAV-3 strains, survival rates drop to a precarious 40-60% [4]. In the presence of MDA, a scenario that mirrors field conditions in progeny from vaccinated breeder flocks, the DHAV-1 vaccine required an additional booster vaccination for day-old ducklings to achieve full protection against heterologous strains, whereas a DHAV-3 vaccine provided complete protection irrespective of MDA presence [4]. This highlights the interference of MDA with live vaccine replication and the superior breadth of the DHAV-3 vaccine’s induced immunity.

Furthermore, the host’s genetic background plays a crucial role in determining vaccine outcome. Pekin and Muscovy ducklings display markedly different susceptibilities and immune responses to DHAV-3 infection. For instance, Muscovy ducklings exhibit significantly higher serum levels of IFN-β and IL-1β following DHAV-3 infection compared to Pekins, suggesting a more robust and potentially more protective innate immune response [13]. The development of a hyper-cytokinemic state, or "cytokine storm," is a hallmark of severe DHAV-1 infection in some breeds, leading to rapid mortality and extensive liver pathology [30]. This implies that a vaccine strategy that is effective in one breed or genetic line may be suboptimal in another, necessitating a more nuanced approach to immunization programs that accounts for host genetic diversity. The identification of specific genetic markers, such as high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels, which correlate with resistance to DHAV-3, opens the possibility of marker-assisted selection of resistant duck lines, thereby complementing vaccination efforts [27].

Towards Next-Generation Vaccines: Broad-Spectrum and Rational Design

Given the deficiencies of classical live attenuated and inactivated vaccines, the field is pivoting towards next-generation platforms that offer the promise of broad-spectrum protection and enhanced safety. The inherent risk of reversion to virulence associated with live attenuated vaccines [15, 23] and the lower immunogenicity of inactivated vaccines [7] have spurred research into recombinant and epitope-based strategies. The use of avian adeno-associated virus (AAAV) as a vector to deliver the DHAV-1 VP1 or VP3 protein has shown considerable promise, inducing systemic immune responses and conferring complete protection against lethal challenge in ducklings, representing a safe and efficacious alternative to live virus [39, 41].

The most ambitious and conceptually advanced strategy is the development of a multi-epitope peptide vaccine designed to overcome genotype-specific immunity. Employing sophisticated immunoinformatics, researchers have screened the proteomes of DHAV-1, DHAV-2, and DHAV-3 to identify conserved and immunodominant linear B-cell epitopes, cytotoxic T-lymphocyte (CTL) epitopes, and helper T-lymphocyte (HTL) epitopes [38]. This rationally designed construct, when expressed recombinantly, induced high-titer antibodies (up to 1:128,000) in immunized animals and demonstrated strong cross-reactivity with recombinant VP proteins from all three genotypes [38]. The sera from vaccinated ducks were able to detect antigenically diverse field strains in Western blot analysis, providing compelling proof-of-concept for a truly pan-genotypic vaccine [38]. Furthermore, the identification of a highly conserved B-cell epitope (¹⁷⁴LPSPTY¹⁷⁹) present in the VP1 protein of all three DHAV-2 strains, and similar to the conserved epitope in DHAV-1, offers a potential target for a universal vaccine component [2, 6]. These innovative approaches, moving from empirical attenuation to rational, structure-guided design, represent the most viable path forward to address the formidable immune evasion challenges posed by this increasingly diverse and economically devastating pathogen. The transition from experimental validation to field application will require rigorous challenge trials with heterologous and recombinant strains, but the foundational science is now in place to fundamentally alter the trajectory of DHAV control.

References

[1] Yehia N, Erfan A, Omar SE, Soliman M. Dual Circulation of Duck Hepatitis A Virus Genotypes 1 and 3 in Egypt. Avian diseases. 2020. DOI: https://doi.org/10.1637/aviandiseases-D-20-00075

[2] Rajendran R, Sundaram RS, Rao PL, Nathan DS, Muthukrishnan M, Manoharan S, et al.. Molecular and phylogenetic analyses of the first complete genome sequence of Duck hepatitis A virus genotype 2 from India.. Gene. 2025. DOI: https://doi.org/10.1016/j.gene.2025.149236

[3] Zhao S, Hao Y, Zhang Q, Li B, Fan Y, Liu G, et al.. Global dissemination and evolutionary dynamics of duck hepatitis A virus type 3 driven by VP1 gene variation.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110770

[4] Kim S, Yu C, Park J, Ma X, Zhu T, Li Y, et al.. The Impact of Genetic Variation on Duck Hepatitis A Virus (DHAV) Vaccine Efficacy: A Comparative Study of DHAV-1 and DHAV-3 Against Emerging Variant Strains. Vaccines. 2024. DOI: https://doi.org/10.3390/vaccines12121416

[5] Chen X, Chen Y, Liu C, Li X, Liu H, Bai X, et al.. One-tube RT-PCR for the Simultaneous Detection and Typing Duck Hepatitis A Virus Subtypes 1 and 3. . 2019. DOI: https://doi.org/10.20944/PREPRINTS201901.0212.V1

[6] Wu X, Li X, Zhang Q, Wulin S, Bai X, Zhang T, et al.. Identification of a Conserved B-Cell Epitope on Duck Hepatitis A Type 1 Virus VP1 Protein. PLoS ONE. 2015. DOI: https://doi.org/10.1371/journal.pone.0118041

[7] Omar DM, Abdrabo MA, Monir NM, Marden NA, Abdelaziz H, Sayed WAE, et al.. Protective Efficacy of a Locally Prepared Bivalent Duck Viral Hepatitis “Serotypes 1 and 3” Inactivated Vaccine. Macedonian Veterinary Review. 2024. DOI: https://doi.org/10.2478/macvetrev-2024-0010

[8] Doan H, Le X, Do RT, Hoang C, Nguyen KT, Le T. Molecular genotyping of duck hepatitis A viruses (DHAV) in Vietnam.. Journal of Infection in Developing Countries. 2016. DOI: https://doi.org/10.3855/jidc.7239

[9] Wang M, Zhang J, Zhou J, Chen H, Ma L, Ding Y, et al.. Analysis of codon usage in type 1 and the new genotypes of duck hepatitis virus. Biosyst.. 2011. DOI: https://doi.org/10.1016/j.biosystems.2011.06.005

[10] Dubovitskiy N, Kurskaya O, Solomatina MV, Loginova A, Derko A, Khozyainova A, et al.. Metagenomic identification, isolation, and complete genome characterization of two novel picornaviruses in wild duck from Northeastern Siberia. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-03017-w

[11] Moharam I, Abaza MA, Khalil NW, El-Nahas E, El-Habbaa A, Najar F, et al.. Complete genome sequencing, molecular and antigenic characterization of duck hepatitis A virus type 1 isolated in Benha, Egypt. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-05010-5

[12] Zhao S, Wu B, Wang Q, Wei X, Liu X, Tang Y, et al.. Advances in the Duck Hepatitis A virus and lessons learned from those in recent years.. Microbial Pathogenesis. 2024. DOI: https://doi.org/10.1016/j.micpath.2024.107018

[13] Shawki MM, Abido OY, Saif MA, Sobh MS, Gado A, Elnaggar A, et al.. Comparative pathogenicity of duck hepatitis A virus genotype 3 in different duck breeds: Implications of the diagnosis and prevention of duck viral hepatitis.. Comparative Immunology, Microbiology & Infectious Diseases. 2024. DOI: https://doi.org/10.1016/j.cimid.2024.102256

[14] Dan Y, Li L, Wang H, Sang S, Zhou B, Wang Z, et al.. Isolation, characterization and whole-genome analysis of a potentially novel strain of duck hepatitis A virus type 3 from a vaccinated duck flock in China. Frontiers in Microbiology. 2026. DOI: https://doi.org/10.3389/fmicb.2026.1775404

[15] Zhang Y, Wu S, Liu W, Hu Z. Current status and future direction of duck hepatitis A virus vaccines. Avian Pathology. 2022. DOI: https://doi.org/10.1080/03079457.2022.2162367

[16] Rohaim M, Naggar RF, Abdelsabour MA, Ahmed BA, Hamoud MM, Ahmed KA, et al.. Insights into the Genetic Evolution of Duck Hepatitis A Virus in Egypt. Animals. 2021. DOI: https://doi.org/10.3390/ani11092741

[17] Hisham I, Ellakany H, Selim A, Abdalla M, El-Abideen MAZ, Kilany WH, et al.. Comparative Pathogenicity of Duck Hepatitis A Virus-1 Isolates in Experimentally Infected Pekin and Muscovy Ducklings. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00234

[18] Hassan T, Eid A, Ghanem I, Shahin A, Adael SAA, Mohamed FF. First Report of Duck Hepatitis A Virus 3 from Duckling Flocks of Egypt. Avian diseases. 2020. DOI: https://doi.org/10.1637/aviandiseases-D-19-00158

[19] Mansour S, Mohamed FF, ElBakrey RM, Eid A, Mor S, Goyal S. Outbreaks of Duck Hepatitis A Virus in Egyptian Duckling Flocks. Avian diseases. 2018. DOI: https://doi.org/10.1637/11975-092118-Reg.1

[20] Chen X, Chen Y, Liu C, Li X, Liu H, Yin X, et al.. Improved one-tube RT-PCR method for simultaneous detection and genotyping of duck hepatitis A virus subtypes 1 and 3. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0219750

[21] Ou X, Mao S, Cao J, Cheng A, Wang M, Zhu D, et al.. Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0178993

[22] Wen X, Cheng A, Wang M, Jia R, Zhu D, Chen S, et al.. Detection, differentiation, and VP1 sequencing of duck hepatitis A virus type 1 and type 3 by a 1-step duplex reverse-transcription PCR assay.. Poultry Science. 2014. DOI: https://doi.org/10.3382/ps.2014-04024

[23] Liu X, Kong X. Isolation, identification and attenuation of a pathogenic duck hepatitis virus type 1 in China, and complete genomic sequence comparison between the embryo-passaged, attenuated derivatives and their parent.. Polish journal of veterinary sciences. 2019. DOI: https://doi.org/10.24425/pjvs.2018.125614

[24] Liang S, Xie M, Tang J, Wang M, Zhang D, Hou S. Proteomics reveals the effect of type I interferon on the pathogenicity of duck hepatitis A virus genotype 3 in Pekin ducks.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108813

[25] Wang M, Li Z, Liu H, Wang X, Zhang D. Effect of fetal calf serum on propagation of duck hepatitis A virus genotype 3 in duck embryo fibroblast cells. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1904-y

[26] Mohamed RI, Mosad SM, Ali HS, Albalawi W, Elsamadony H, Ramzy N, et al.. A comprehensive pathological and molecular investigation of viral co-infections in ducks in Egypt. Frontiers in Microbiology. 2025. DOI: https://doi.org/10.3389/fmicb.2025.1522669

[27] Liang S, Chang Z, Lu M, Guo Z, Luo D, Xing G, et al.. Host lipid metabolism influences the variation in resistance of Pekin ducks to duck hepatitis A virus genotype 3.. International Journal of Biological Macromolecules. 2024. DOI: https://doi.org/10.1016/j.ijbiomac.2024.139168

[28] Zhao H, Wu Z, Wang Z, Ru J, Wang S, Li Y, et al.. Genomic Landscape and Regulation of RNA Editing in Pekin Ducks Susceptible to Duck Hepatitis A Virus Genotype 3 Infection. International Journal of Molecular Sciences. 2024. DOI: https://doi.org/10.3390/ijms251910413

[29] Liang S, Lu M, Yu D, Xing G, Ji Z, Guo Z, et al.. Effects of age on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks by 16 S and transcriptomics. Computational and Structural Biotechnology Journal. 2024. DOI: https://doi.org/10.1016/j.csbj.2024.01.005

[30] El-Sayed HS, Saad A, Tawfik WA, Adel A, Abdelmagid M, Momenah M, et al.. The role of turmeric and black pepper oil nanoemulsion in attenuating cytokine storm triggered by duck hepatitis A virus type I (DHAV-I)-induced infection in ducklings. Poultry Science. 2023. DOI: https://doi.org/10.1016/j.psj.2023.103404

[31] Liang S, Zhang J, Wang X, Xing G, Guo Z, Zhang Q, et al.. Selective analysis of resistance and susceptibility to duck hepatitis A virus genotype 3 in Pekin duck. Animal Research and One Health. 2023. DOI: https://doi.org/10.1002/aro2.36

[32] Liang S, Hu X, Guo Z, Luo D, Tang J, Ji Z, et al.. Comparative transcriptome reveals the effect of IFITM1 on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks.. Virus Research. 2022. DOI: https://doi.org/10.1016/j.virusres.2022.198930

[33] Liang S, Wang M, Zhang B, Feng Y, Tang J, Xie M, et al.. NOD1 Is Associated With the Susceptibility of Pekin Duck Flock to Duck Hepatitis A Virus Genotype 3. Frontiers in Immunology. 2021. DOI: https://doi.org/10.3389/fimmu.2021.766740

[34] Liang S, Tang J, Wang X, Wen Z, Xie M, Wu Y, et al.. Effect of duck hepatitis A virus genotype 3 infection on glucose metabolism of Pekin ducklings and underlying mechanism.. Gene. 2020. DOI: https://doi.org/10.1016/j.gene.2020.144710

[35] Wang M, Chai L, Liang S, Lv J, Yang L, Qu S, et al.. Fetal Calf Serum Exerts an Inhibitory Effect on Replication of Duck Hepatitis A Virus Genotype 1 in Duck Embryo Fibroblast Cells. Viruses. 2020. DOI: https://doi.org/10.3390/v12010080

[36] Wang X, Zhang J, Meng R, Jiang Y, Liang S, Zhang Y, et al.. Host Differences Affecting Resistance and Susceptibility of the Second Generation of a Pekin Duck Flock to Duck Hepatitis A Virus Genotype 3. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.01128

[37] Tang C, Lan D, Zhang H, Ma J, Yue H. Transcriptome Analysis of Duck Liver and Identification of Differentially Expressed Transcripts in Response to Duck Hepatitis A Virus Genotype C Infection. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0071051

[38] Yang Y, Chen X, Liu A, He J, Cao Y, He P. A Highly Immunogenic and Cross-Reactive Multi-Epitope Vaccine Candidate Against Duck Hepatitis A Virus: Immunoinformatics Design and Preliminary Experimental Validation. International Journal of Molecular Sciences. 2025. DOI: https://doi.org/10.3390/ijms262210958

[39] Wang A, Liu L, Gu L, Guo C, Wu S, Feng Q, et al.. Protection against duck hepatitis a virus type 1 conferred by a recombinant avian adeno‐associated virus. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pey325

[40] Zanaty A, Hagag N, Samy M, Abdel-Halim A, Soliman M, Arafa A, et al.. Molecular and pathological studies of duck hepatitis virus in Egypt. . 2017. DOI: https://doi.org/10.21608/JVMR.2017.43283

[41] Wang A, Liu L, Gu L, Wu S, Guo C, Feng Q, et al.. Expression of duck hepatitis A virus type 1 VP3 protein mediated by avian adeno-associated virus and its immunogenicity in ducklings.. Acta virologica. 2019. DOI: https://doi.org/10.4149/av_2019_104